Cited by 404Fatty Acid Research and HealthTryptophan and brain disordersTreatment of Major Depression

Efficacy of omega-3 PUFAs in depression: A meta-analysis

Open access
Liao, Yuhua, Xie, Bo, Zhang, Huimin, He, Qian, Guo, Lan, Subramanieapillai, Mehala, Fan, Beifang, Lu, Ciyong +1 more·2019·Translational Psychiatry

Abstract

We conducted this meta-analysis of double-blind randomized placebo-controlled trials to estimate the efficacy of omega-3 polyunsaturated fatty acids (PUFAs), especially docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), in the improvement of depression. We applied a systematic bibliographic search in PubMed and EMBASE for articles published prior to 20 December 2017. This meta-analysis was performed using RevMan 5.3 and R 3.4.3, and means and standard deviations were calculated in fixed- or random-effects models based on the results of the Q-test. A sensitivity analysis was also conducted to evaluate the stability of the results, and publication bias was evaluated by a funnel plot and Egger’s linear regression analysis. Our search resulted in 180 articles; we analyzed 26 studies, which included 2160 participants. The meta-analysis showed an overall beneficial effect of omega-3 polyunsaturated fatty acids on depression symptoms (SMD = −0.28,P = 0.004). Compared with placebo, EPA-pure (=100% EPA) and EPA-major formulations (≥60% EPA) demonstrated clinical benefits with an EPA dosage ≤1 g/d (SMD = −0.50,P = 0.003, and SMD = −1.03,P = 0.03, respectively), whereas DHA-pure and DHA-major formulations did not exhibit such benefits. Current evidence supports the finding that omega-3 PUFAs with EPA ≥ 60% at a dosage of ≤1 g/d would have beneficial effects on depression. Further studies are warranted to examine supplementation with omega-3 PUFAs for specific subgroups of subjects with inflammation, severity of depression, and the dose response for both EPA and DHA supplementation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41398-019-0515-5

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 55 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. [13]Higgins. in Cochrane Handbook for Systematic Reviews of Interventions (version:5.1.0) (eds Higgins, J. P. T. & Green, S.) (Chichester, UK: The Cochrane Collaboration & John Wiley & Sons, Ltd. 2011). http://handbook-5-1.cochrane.org/.
  2. [16]Peet M Horrobin DF Group EEMS. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms J. Psychiatr. Res. 2002 36 7 10.1016/S0022-3956(01)00048-6 11755456 · DOI

Cited by

Sorted by citations

Authors
Liao, Y., Xie, B., Zhang, H., He, Q., Guo, L., Subramanieapillai, M., Fan, B., Lu, C., & McIntyre, R. S.
Affiliations
  • Shenzhen Nanshan Center for Chronic Disease Control (CN)
  • Sun Yat-sen University (CN)
  • University Health Network (CA)
Corresponding author
  • Fan, Beifang
  • Lu, Ciyong
Venue
Translational Psychiatry
Published
2019-08-05
Volume
9
Issue
1
Pages
190-190
ISSN
2158-3188 (ISSN-L)
OpenAlex
W2965334743
Cited by
404
References
55
Citations by year
2026: 35 · 2025: 62 · 2024: 75 · 2023: 77 · 2022: 65 · 2021: 52 · 2020: 35 · 2019: 2 · 2014: 1
FWCI
5.23
Type
journal article
Language
en
Open access
Locations
  • Translational Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Natural Science Foundation of China
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Keywords
omega-3 polyunsaturated fatty acids, depression, docosahexaenoic acid, eicosapentaenoic acid, DHA supplementation, dietary supplementation, depressive symptoms, dose-response relationship
MeSH terms
Depressive Disorder, Double-Blind Method, Humans, Fatty Acids, Omega-3, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review